PXD101 and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: PXD101 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Isotretinoin may cause solid tumor cells to look more like normal cells, and to grow and spread more slowly. Giving PXD101 together with isotretinoin may be an effective treatment for metastatic or unresectable solid tumors.
PURPOSE: This phase I trial is studying the side effects and best dose of PXD101 when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific |
Drug: belinostat |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies |
- 1.1.1 To assess the safety and feasibility of combining PXD101 with 13-cis-retinoic acid (13-cRA) in patients with advanced solid tumor malignancies. [ Time Frame: end of study ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 36 |
| Study Start Date: | June 2006 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
-
Drug: belinostat
OBJECTIVES:
Primary
- Determine the safety and tolerability of PXD101 when administered with isotretinoin in patients with metastatic or unresectable solid tumors.
- Determine the maximum tolerated dose of PXD101 when administered with isotretinoin in these patients.
- Determine the toxic effects of this regimen in these patients.
- Determine the pharmacokinetics of this regimen in these patients.
Secondary
- Demonstrate upregulation of retinoic acid receptor-beta and retinoic X-receptor expression in tumor tissue from patients treated with this regimen.
- Correlate apoptosis in tumor tissue with tumor response in patients treated with this regimen.
- Determine the change in gene expression after exposure to this regimen.
- Determine any clinical activity of this regimen in these patients.
OUTLINE: This is a multicenter, dose-escalation study of PXD101.
Patients receive PXD101 IV over 30 minutes on days 1-5 and oral isotretinoin once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of PXD101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.
Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic* studies.
All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies.
After completion of study treatment, patients are followed for ≥ 8 weeks.
NOTE: * A subset of patients also undergo blood collectiion for pharmacokinetic studies of PXD101, at the highest dose levels even though MTD has not been reached, with or without isotretinoin.
PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed solid tumor
- Metastatic or unresectable disease
- Refractory to standard curative or palliative treatments or these treatments do not exist
- No known brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%
- Life expectancy > 3 months
- WBC ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception prior to, during, and for 30 days after completion of study treatment
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD101
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled illness
- No marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 500 msec)
- No long QT syndrome
No significant cardiovascular disease, including any of the following:
- Unstable angina pectoris
- Uncontrolled hypertension
- Congestive heart failure related to primary cardiac disease
- Any condition requiring anti-arrhythmic therapy
- Ischemic or severe valvular heart disease
- Myocardial infarction within the past 6 months
PRIOR CONCURRENT THERAPY:
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered
- At least 2 weeks since prior valproic acid
- No other concurrent investigational agents
- No other concurrent anticancer agents or therapies
No concurrent medication that may cause torsades de pointes, including any of the following:
- Disopyramide
- Dofetilide
- Ibutilide
- Procainamide
- Quinidine
- Sotalol
- Bepridil
- Amiodarone
- Arsenic trioxide
- Cisapride
- Lidoflazine
- Clarithromycin
- Erythromycin
- Halofantrine
- Pentamidine
- Sparfloxacin
- Domperidone
- Droperidol
- Chlorpromazine
- Haloperidol
- Mesoridazine
- Thioridazine
- Pimozide
- Methadone
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No prophylactic filgrastim (G-CSF) during the first course of study treatment
Contacts and Locations| United States, California | |
| City of Hope Comprehensive Cancer Center | Recruiting |
| Duarte, California, United States, 91010-3000 | |
| Contact: Clinical Trials Office - City of Hope Comprehensive Cancer Cen 800-826-4673 becomingapatient@coh.org | |
| USC/Norris Comprehensive Cancer Center and Hospital | Recruiting |
| Los Angeles, California, United States, 90089-9181 | |
| Contact: Clinical Trials Office - USC/Norris Comprehensive Cancer Cente 323-865-0451 | |
| Contra Costa Regional Medical Center | Recruiting |
| Martinez, California, United States, 94553 | |
| Contact: Sharon Hiner, MD 925-370-5114 shiner@hsd.co.contra-costa.ca.us | |
| University of California Davis Cancer Center | Recruiting |
| Sacramento, California, United States, 95817 | |
| Contact: Clinical Trials Office - University of California Davis Cancer 916-734-3089 | |
| United States, Pennsylvania | |
| UPMC Cancer Centers | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| Contact: Clinical Trials Office - UPMC Cancer Centers 412-647-8073 | |
| Study Chair: | Thehang H. Luu, MD | Beckman Research Institute |
More Information
Additional Information:
No publications provided
| Responsible Party: | California Cancer Consortium |
| ClinicalTrials.gov Identifier: | NCT00334789 History of Changes |
| Other Study ID Numbers: | CDR0000479715, U01CA062505, CCC-PHI-53, NCI-7251 |
| Study First Received: | June 7, 2006 |
| Last Updated: | February 16, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by California Cancer Consortium:
|
unspecified adult solid tumor, protocol specific |
Additional relevant MeSH terms:
|
Neoplasms Isotretinoin Dermatologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on October 16, 2012
